Can we build a roadmap to conquer Multiple Sclerosis (MS), a disease that impacts more than 2 million globally as the leading non-traumatic disability disorder in young adults?
WXPress is your window into the world of WuXi AppTec and our global partners. WXPress gives you an insider’s perspective on our collaborative efforts to develop innovative medicines that improve the lives of patients.
In the past few years, the field of cell and gene therapy has witnessed major breakthroughs. It has become one of the hottest fields in the biotech industry, with the […]
WuXi AppTec is convening and working together with experts, from our company and around the world, for ongoing analysis of the COVID-19 pandemic. We are also partnering with other industry […]
This complimentary webinar will convene leading physicians, drug developers, patients and advocates. These experts will discuss the latest advances in the development of transformative medicines for hemophilia, including gene therapy and next generation technologies.
In honor of World Neurofibromatosis (NF) Awareness Month, the WuXi AppTec community is proud to join the millions around the world working to enhance our understanding of this rare disease.
WuXi AppTec hosted the second online forum on the COVID-19 pandemic, titled “Harnessing Our Collective Power”, which attracted 2487 viewers via Zoom and 112,000 viewers via live streaming from 37 countries and regions.
This 18-speaker forum created a strong platform for professionals within industry and academia to discuss the challenges seen in the global management of the COVID-19. Topics such as: diagnosis, therapeutic intervention, vaccine development and global preparedness were keenly discussed in conjunction with patient-focused solutions.
During Day two, we took a look at health beyond therapy alone. Tomorrow’s healthcare will go far further than prescribing drugs or performing surgery, it’s about bringing in the wider […]
The opening day agenda focused on novel medicines. We explored how science, technology, and entrepreneurship is driving a new age of geographically dispersed innovators, operating internationally to “bridge productivity” and […]
WuXi Healthcare Forum 2019 Meeting Tomorrow’s Health Challenges March 5-6, 2019 | St. Regis Shanghai For registration details, please visit the Forum website. We are at the dawn of a […]
WuXi Healthcare Forum 2019 Inspired by Meeting Tomorrow’s Health Challenges March 5-6, 2019 | St. Regis Shanghai Registration and full agenda, please click here. We are at the dawn of a […]
In this panel discussion, we bring together leaders in machine learning and artificial intelligence in drug discovery and development to delve into the opportunities, capabilities, future trends and challenges of using AI to speed up drug discovery, decrease failure rates in drug trials, and create more affordable and better treatments for patients.
The Marketing Authorization Holder System in China will expedite market access to the world’s second largest pharmaceutical economy, by allowing license holders of a drug to sell in China using a contract manufacturer.
Join us at ChinaBio® Partnering Forum 2017 May 31 – June 1, to meet hundreds of biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering in Zhuhai.
Now in its eighth year, the WuXi Global Forum at the J.P. Morgan Healthcare Conference brings together thousands of leaders to promote new thinking on a global stage as we […]
Into its seventh year, WuXi Global Forum 2019 continues its tradition of bringing together thousands of leaders onsite and via live broadcasting to promote new thinking on a global stage.
Now in its sixth year, WuXi Global Forum 2018 takes place during the J.P. Morgan Healthcare Conference, with industry thought leaders discussing rapid advancements and changes impacting the industry, from […]
WuXi Global Forum 2017, now in its fifth year, brings together 1,000 industry leaders to find transformative models and solutions for patients, at a time when stakes are higher than […]
The life science industry is entering a renewed age of innovation in 2015. Collectively, we have delivered strong results on almost every front, buoyed by breakthrough therapies and scientific advancements. […]
To many, 2014 is a year of renewed energy and growth. Global partnerships at all levels are breaking down barriers to innovation, as the convergence of health and technology starts […]
2013 has been a great year in the world of pharmaceutical and biotech R&D. While we are still facing mounting productivity challenges, many have come to understand that any single […]
The new laboratory will increase industry testing capacity for cell and gene therapies, enabling faster and more effective development, manufacturing and delivery to patients. November 18, 2020 – Philadelphia, PA […]
WuXi AppTec Third-Quarter 2020 ResultsRevenue Growth Accelerated to 35.4% Year-Over-Year to RMB 4,583 MillionAdjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 44.3% Year-Over-Year to RMB 958 MillionAdjusted Diluted Non-IFRS EPS Up 37.9% YoY to RMB0.40 WuXi […]
WuXi AppTec Second-Quarter 2020 Results Net Profit Attributable to Owners of the Company Up 111.0% YoY to RMB1,414 Millio Diluted EPS Up 110.3% YoY to RMB0.61 Adjusted Non-IFRS Net Profit Attributable […]
SHANGHAI and PHILADELPHIA, June 1, 2020 — WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang […]
World-class platform will enable biotechnology companies and researchers to accelerate the development, manufacturing and release of cell and gene therapies for patients May 18, 2020 – Philadelphia, PA – WuXi […]
Revenue Up 15.1% Year-Over-Year to RMB3,188 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 10.8% Year-Over-Year to RMB576 Million Adjusted Diluted Non-IFRS EPS Up 9.4% Year-Over-Year […]
WuXi AppTec Reports Strong 2019 Annual Results Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 38.2% Year-Over-Year to RMB2,407 […]
SHANGHAI, March 12, 2020 – WuXi AppTec announced that the company’s Wuhan site resumed operations yesterday, in compliance with local regulations and global COVID-19 health and safety guidelines. Operations at […]
WuXi AppTec China Sites Resume Operations after Extended Lunar New Year Holiday SHANGHAI, February 12, 2020 – With the end of the extended Lunar New Year holiday, WuXi AppTec sites […]
New AAV Vector Suspension platform complements integrated capabilities – enabling cell and gene therapies to be developed, manufactured, and released faster and with greater predictability globally. January 13, 2020 – […]